{"name":"Entera Bio Ltd.","slug":"entera-bio-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":42000,"revenueGrowth":-76.8,"grossMargin":0,"rdSpend":6004000,"netIncome":-11439000,"cash":15993000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Oral PTH (1-34)","genericName":"Oral PTH (1-34)","slug":"oral-pth-1-34","indication":"Osteoporosis in postmenopausal women","status":"phase_3"},{"name":"EBP05","genericName":"EBP05","slug":"ebp05","indication":"Short bowel syndrome","status":"phase_2"},{"name":"EBP11-F1","genericName":"EBP11-F1","slug":"ebp11-f1","indication":"Other","status":"phase_1"},{"name":"EBP22","genericName":"EBP22","slug":"ebp22","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Oral PTH (1-34)","genericName":"Oral PTH (1-34)","slug":"oral-pth-1-34","phase":"phase_3","mechanism":"Oral PTH (1-34) activates parathyroid hormone receptors on bone cells to stimulate bone formation and increase bone mineral density.","indications":["Osteoporosis in postmenopausal women","Osteoporosis in men at high risk of fracture"],"catalyst":""},{"name":"EBP05","genericName":"EBP05","slug":"ebp05","phase":"phase_2","mechanism":"EBP05 is a recombinant human glucagon-like peptide-2 (GLP-2) analog.","indications":["Short bowel syndrome"],"catalyst":""},{"name":"EBP11-F1","genericName":"EBP11-F1","slug":"ebp11-f1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EBP22","genericName":"EBP22","slug":"ebp22","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxObjlPMVdYNHNabUdwMjBCWjZsVTJrOFZvdmRmQW02NThkdTQtTG1nRUZ3ZmxWQXFGdWFnMnUzaTRiMWExbEc3bDZoRWJhREhyakhtc1hHdFpPelFHR0xHVzR1Y0ZWZS1teTdZaVpEWDlORHREV3U4azBwY1NwbkpFb2ltT2pfU0lfNHlJUw?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Hypoparathyroidism Pipeline 2026: Therapies Under - openPR.com","headline":"Hypoparathyroidism Pipeline 2026: Therapies Under","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1rVG9xNDNLMVFmRkpfS3Q2ZG85T2tQMEg1a011SFBjd1BOUnkxWllBWllVVVFNVy1XTVBXOFVEM3I1cGp2eU44MlM5eVp5OUZEcm5uNGoxZ2l3cUJQbXBZ?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"ENTX Stock Price, Quote & Chart | ENTERA BIO LTD (NASDAQ:ENTX) - ChartMill","headline":"ENTX Stock Price, Quote & Chart | ENTERA BIO LTD (NASDAQ:ENTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOMmRBZk1iTmJoZVBjSWpuZzVrQ1hzWTNmbC1NXzdVZmk0TVEwcUFIMjFrWXJLb0ZaN0o4UDNRVUJhbVpnenhReEZBdHdIdW4wNWxrVmFIZWROczZKWDlGZTdlVU93UHhMWVBTR01SOEdURzdDT1gxZ2NzRFpBemExOWdmek02cU5JdkJYd3FwZW5vakxwZ2NTZ3lHSjl6d0xMaDA0?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"Entera Bio (NASDAQ: ENTX) outlines oral osteoporosis and metabolic pipeline - Stock Titan","headline":"Entera Bio (NASDAQ: ENTX) outlines oral osteoporosis and metabolic pipeline","sentiment":"neutral"},{"date":"2026-03-27","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9SVlVVc2U4WldHbTkxUnBHUWJBTm1SaWIzNXZ4NjAzekpnRS1yOGlHNUU2Z21mTDF0X2c4dHVybGZxaF9LRndDMF90eVFfRjdOZjFoeDdPQXVNdFFTOVhCZGlmVElXem9vVThjOG96blBvREZwOG9fal9xQ1dhSGM?oc=5","date":"2026-03-16","type":"pipeline","source":"Fortune Business Insights","summary":"Oral Biologics Drugs Market Size, Share | Industry Report [2034] - Fortune Business Insights","headline":"Oral Biologics Drugs Market Size, Share | Industry Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQT3RuU3dZRUhWY25ReFYxMGw2QTJlcU9Ra0FVY1VZNEJjeElud092eXdUWW94aEh4aFl5ZDRDczdkajE5eFlDR2Y5ZHhEempJck1xdlFGUFYxT0pya3NlSktUUjM4Y2RSc3ViOWhyZWxZbGRWMlhzOGU2Z0VUWDZ5NnpuUjZiUXNnS1ViaTgxY2J1ei1vUFd5TEJuNkxPczYwODhFWDZsU1NqT1FQZ3ZZYndKbldoU1h3RllqajR6YWs5OWN0bzBpRmtaTTduMUFEMDlxel93ckZuV29r?oc=5","date":"2026-03-05","type":"trial","source":"TipRanks","summary":"Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX) - TipRanks","headline":"Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOVzRyNUQxOHFmYndHQ0xFc283MkJZWTNaekFONG1oTmhmVWpib2xvdm1tQlBWMUh4cmdmOGd4YXVPc0dtVW9USlYyZWFTd1liLTJKZDNRNzBXWjdvOEx2OUZTZ01uYy1hN2VpaWRUZm5jcnJpenJBSFlXV2hEY0FxaThIaEZZd0p0MXlIako2MDh4M0pLbTljVk1TNk5WOXcyTG5NSGdCNkN6NXFocjBSNGFRRHRXUzdPNVB0Q1lnUQ?oc=5","date":"2026-02-18","type":"deal","source":"TradingView","summary":"Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? - TradingView","headline":"Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQWHQweUt3dDNFOWh4R0hvSHB5Z2lqaTNEMy12bGdPZkVWMlhtcGx1bXdTamFpZzZlOGJoUkd0Z2p1MFByc3JYQW8yOUxQQ0NNdVR2UXgtWC1uWnlRdUxqM01FZm5YamNvbWxEWGY1U1BCSXQxQnpFSWhfdE9XMmZJQkRQSkVfWkVoRkxldFVoX0xxWm54MGdTbWdGM1lZSm9WRF95S0w0UTljdUJDXzdIdGJQeWZLZ0E?oc=5","date":"2026-02-09","type":"trial","source":"Stock Titan","summary":"Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned - Stock Titan","headline":"Ex-Pfizer exec to lead Entera Bio board as 2026 oral PTH trials planned","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNX1lsLXl5S2R1ekdoOXZuNlU3SmRNWkJ2aXZIZG5ZY1ktMW5uUWp2QmxyMWFzQ0dJTEM5bnFybmN4elhYWndtN2ZSR2RZM01DdnNXeXVlb1NiNUtkaVYtRjJmV29UU3hFU1RDNkJha1cyVmxndVpJUmdwZjVsSGo2TGJWTXZWU1BDR25QX2ItT00zSVR4QUwzZ3NTZllEOEgyR0tGYVNZODhheksyaDRaMlRkaw?oc=5","date":"2025-12-30","type":"deal","source":"Quiver Quantitative","summary":"Entera Bio Ltd. Stock (ENTX) Opinions on Insider Buying and Clinical Updates - Quiver Quantitative","headline":"Entera Bio Ltd. Stock (ENTX) Opinions on Insider Buying and Clinical Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPNmp3S0Zuc3R4UDg1OGlGb3EyRWQ4QXpQeFBmQWw4N0QyRjNybEF5X0NGX0pyX2dxY0ctN1RTUFkzVFg4SDNKaldUOWZCNkY1RmlpS2NEYXc1V2M3Q1dIZFRKOHJFSzdqNmhIRUFmdFlBVHdMUWtySlYyWkRrdlpKZk9GNlRCNzU3QnRYbUVyWXN0WG5acVZjZ3B5U0l0VHBZUlVWVw?oc=5","date":"2025-11-14","type":"pipeline","source":"industrytoday.co.uk","summary":"Oral Proteins and Peptides Market Know the Scope and Trends - industrytoday.co.uk","headline":"Oral Proteins and Peptides Market Know the Scope and Trends","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"phase_2":1,"phase_1":2},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":42000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":42000,"period":"2025-12-31"},{"value":181000,"period":"2024-12-31"},{"value":181000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6004000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-11439000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":15993000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}